Grünenthal is a global leader in pain management. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

A mix of strong entrepreneurial spirit, close collaboration, and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

We believe compliance, ethics and transparency go hand in hand. Excellence in this area is a key topic for us – and is deeply anchored in our culture.

... Compliance and transparency

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Partnering

In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

Being a responsible corporate citizen means operating our business legally, ethically, respectfully and sustainably. All business areas collaborate cross-functionally to manage environmental, social and governance (ESG) risks and make a net-positive impact in our focus areas of Patient, People and Planet.

... Responsibility

At Grünenthal, our vision of a World Free of Pain aligns seamlessly with our commitment to sustainability, especially the social aspect. We regularly evaluate our products, services, and markets to ensure alignment with our sustainability objectives.

... Our responsibility approach

Grünenthal’s focus on patients is at the core of our responsibility approach. We concentrate our efforts on the key areas of patient safety, product quality, improving patients’ quality of life through innovative medicines, access to healthcare and safe pain management through the responsible use of opioids.

... Patient

How can we have a positive impact on the lives of the people we work with, our partners and wider society? Find out what we do to foster trust and promote diversity and inclusion, how we empower our employees to be their best and look after their health and wellbeing, and how we contribute to improving the quality of life for people and communities around us.

... People

We join together with our employees, partners and customers to reduce our carbon footprint, save energy and resources, and decrease waste in our value chain.

... Planet

The Grünenthal Responsible Sourcing Programme will increase transparency and help create a positive ESG impact in our supply chain and connected local communities.

... Responsible sourcing

... Corporate Citizenship

... Thalidomide

Our company has a clear vision of a world free of pain and we maintain a laser-sharp focus on this vision in everything we do – especially in our research and development activities.

... Science

We follow a holistic and solution-agnostic approach to deliver highly effective pain treatments, building our programmes on a firm foundation of human pathophysiology and solid human target validation.

... R&D approach

... Collaboration

To move closer to our vision of a world free of pain, we are currently pursuing a range of programmes across different modalities, targets and mechanisms of action.

... Pipeline

As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available.

... Clinical trials

Explore our media section and access a range of materials relating to our company.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2019 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Out now: Grünenthal Report 2025/2026

Grünenthal is a global leader in pain management.

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.

Grünenthal at a glance – experience our virtual company showcase

Who are we? What are we doing? How are we doing it? Our digital company overview quickly answers big questions about Grünenthal.
Read about our key objectives and activities, as well as our recent business development highlights and financial performance. Get insights into our leadership team, strategy and financials, R&D & Pipeline, Product portfolio, Reliable Supply, Environmental & Societal Governance, and our Company culture and purpose.

Visit company showcase

Katrin Fleischer, Global Regulatory Strategy

Sabine Hess, Technician Cellular & Molecular Biology

Andrew Lockhart, Head Translational and Disease Understanding Unit

Grünenthal Stories

View All

Grünenthal’s Head of Global Operations discusses Global Operations strategy for 2030.

GO2030: powering future success

Victor Barbosa, Head of Global Operations at Grünenthal, shares how with GO2030, GO will build on the success of GO2025 to drive cost leadership, integration excellence, and best‑in‑class safety and quality.

25 March 2026

GO team collaborating in our Aachen site

GO2025: A transformation journey

GO2025 marked a fundamental transformation of Global Operations. Over five years, teams worldwide evolved processes, culture, and capabilities—strengthening Grünenthal’s end-to-end value chain and positioning GO as a key driver of growth.

20 March 2026

Integration excellence in action

Our Global Operations team completed and advanced several major integration projects in 2025, while also laying the groundwork for future growth.

16 March 2026

End‑to‑end pharmaceutical supply chain resilience

Supply resilience end‑to‑end

In a volatile global environment, Grünenthal strengthens end‑to‑end supply chain resilience to ensure patients have reliable access to medicines. A data‑driven approach, strong partnerships and proactive teams help anticipate and mitigate risks before they arise.

10 March 2026

Grünenthal API Manufacturing Site Switzerland

Towards sustainable API production

At our Mitlödi site, seven interconnected heat pumps now generate all production heat with green electricity, cutting energy use by 38%.

06 March 2026

Science Made Me… Keith Phillips

Keith Phillips has science in his genes – Grünenthal’s Head of New Modalities leads an international team motivated to create life-changing treatments for pain patients. Together, they are on a journey to unlock genetic medicine approaches for the pain management of tomorrow.

10 February 2026

Grünenthal experts from a variety of disciplines constantly search for new substances that could become active ingredients of innovative pain therapies

Fascination for research and innovation

Grünenthal pursues its vision of a World Free of Pain through extensive research and development. Experts from a variety of disciplines constantly search for new substances that could become active ingredients of innovative pain therapies – driven by the needs of millions of people who suffer from chronic pain around the world.

100 Reasons for a World Free of Pain

First-In-Human Trial with Na_V 1.8 inhibitor

We enrolled the first healthy volunteers in a Phase I trial of our proprietary voltage-gated sodium channel (Na_V) 1.8 inhibitor. With this orally administered investigational medicine, we strive to provide a non-opioid therapy option across a range of acute and chronic pain conditions. The results of the trial are expected later in 2026.

Learn more about how we are driving progress in the advancing field of NaV inhibitors and our latest clinical trial

Grünenthal Report 2025/26

Grünenthal is driven by a clear and ambitious vision: a World Free of Pain. In 2025, we made significant progress in advancing innovative medicines for patients living with pain worldwide.

The Grünenthal Report is a way we share updates on our collective projects, priorities, and progress. It provides an overview of our continued efforts to move closer to our vision.

The full Grünenthal Report is available here.

Responsibility Report 2025/26

As a recognised leader in environmental, social, and governance (ESG) matters, we proactively pursue best-in-class corporate sustainability practices. This report reflects the accomplishments of our teams worldwide around our focus areas of Patient People and Planet. Discover how our shared commitment is shaping long-term value.

Get more insights in our latest Responsibility Report